{
  "label": "clinical_signal_03_ep_004",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:6a1f7e5f19dccf6a963529d5ded32bcc6d7405f573da2d8a5f324e605a9901d1",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:54:15.547583",
  "content": "## 2024-03-25 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 100\n- Active: 98\n- Screen Failures Cumulative: 11\n- Withdrawals Cumulative: 2\n\n#### Sites\n- Site 01 Enrolled: 10\n- Site 01 Active: 10\n- Site 01 Statin Concomitant: 2\n- Site 02 Enrolled: 7\n- Site 02 Active: 7\n- Site 02 Statin Concomitant: 1\n- Site 03 Enrolled: 9\n- Site 03 Active: 9\n- Site 03 Statin Concomitant: 2\n- Site 04 Enrolled: 6\n- Site 04 Active: 6\n- Site 04 Statin Concomitant: 1\n- Site 05 Enrolled: 8\n- Site 05 Active: 8\n- Site 05 Statin Concomitant: 2\n- Site 06 Enrolled: 5\n- Site 06 Active: 5\n- Site 06 Statin Concomitant: 1\n- Site 07 Enrolled: 11\n- Site 07 Active: 11\n- Site 07 Statin Concomitant: 3\n- Site 08 Enrolled: 7\n- Site 08 Active: 7\n- Site 08 Statin Concomitant: 2\n- Site 09 Enrolled: 8\n- Site 09 Active: 8\n- Site 09 Statin Concomitant: 2\n- Site 10 Enrolled: 6\n- Site 10 Active: 6\n- Site 10 Statin Concomitant: 2\n- Site 11 Enrolled: 9\n- Site 11 Active: 9\n- Site 11 Statin Concomitant: 2\n- Site 12 Enrolled: 7\n- Site 12 Active: 7\n- Site 12 Statin Concomitant: 1\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 24.6\n- ALT (U/L) Median: 23.8\n- AST (U/L) Mean: 23.6\n- AST (U/L) Median: 23.2\n- Bilirubin (mg/dL) Mean: 0.86\n- Bilirubin (mg/dL) Median: 0.84\n- ALP (U/L) Mean: 73.7\n- ALP (U/L) Median: 63.8\n- Creatinine (mg/dL) Mean: 1.06\n- Creatinine (mg/dL) Median: 0.92\n- BUN (mg/dL) Mean: 13.3\n- BUN (mg/dL) Median: 13.0\n- WBC (K) Mean: 8.2\n- WBC (K) Median: 5.5\n- Platelets (K) Mean: 235\n- Platelets (K) Median: 234\n\n#### Non-Statin Subgroup\n- N: 122\n- ALT (U/L) Mean: 24.6\n- ALT (U/L) Median: 23.1\n- AST (U/L) Mean: 24.7\n- AST (U/L) Median: 22.8\n- Bilirubin (mg/dL) Mean: 0.7\n- Bilirubin (mg/dL) Median: 0.68\n- ALP (U/L) Mean: 59.4\n- ALP (U/L) Median: 54.2\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.8\n- BUN (mg/dL) Mean: 14.8\n- BUN (mg/dL) Median: 11.5\n- WBC (K) Mean: 7.6\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 243\n- Platelets (K) Median: 244\n\n### Adverse Events\n- AE ID: AE-0011, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0012, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-009, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_05\n- PD ID: PD-010, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_06\n- PD ID: PD-011, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_10\n\n### Investigator Notes\n- No new safety signals identified this week by local PI\n- Site pharmacy inventory verified\n- Query resolution rate at 94%\n\n### Events\n- Data management plan revision v2.2 distributed\n- IVRS system update deployed, randomization unaffected\n\n### Notes\n- Week 4: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_004",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-03-25T10:00:00",
    "phase": "baseline",
    "signal_density": "none",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}